anti-inflammatory therapies living meta-analysis of clinical studies

demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only

	COVID 19 hospitalized
	COVID-19 mild to moderate
anti-inflammatory therapies
clarithromycine	Rashad ...
colchicine	COL-COVID ...
non-steroidal anti-inflammatory drugs	Guzman-Esquivel
Indomethacin	Ravichandran

5423	Jeong, 2020	1	15	0		not a RCT	risk of bias not avaialble
5477	Lund, 2020	1	15	0		not a RCT	risk of bias not avaialble
5510	Malgorzata, 2020	1	13	4		not a RCT	high risk of bias
5555	Scarsi, 2020	1	13	0		not a RCT	risk of bias not avaialble
6010	Gendelman, 2020	1	13	0		not a RCT	risk of bias not avaialble
6028	Abu Esba LC (any NSAID use, acute and chronic), 2020	1	10	0		not a RCT	risk of bias not avaialble
6036	Esba, 2020	0	10	0	selection pending
6186	Gianfransesco, 2020	1	11	0		not a RCT	risk of bias not avaialble
6188	Bruce, 2020	1	10	0		not a RCT	risk of bias not avaialble
6189	Chandan, 2020	1	15	0		not a RCT	risk of bias not avaialble
6691	Tsiakos, 2020	1	31	3		not a RCT	high risk of bias
6960	Imam, 2020	1	13	0		not a RCT	risk of bias not avaialble
6994	Park, 2021	1	12	0		not a RCT	risk of bias not avaialble
7011	Drake, 2021	1	10	0		not a RCT	risk of bias not avaialble
7072	Kragholm, 2021	0	13	0	selection pending
9868	Brunetti, 2020	1	11	0		not a RCT	risk of bias not avaialble
9869	Sandhu, 2020	1	10	0		not a RCT	risk of bias not avaialble
9870	Manenti, 2021	1	13	0		not a RCT	risk of bias not avaialble